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HISTORY OF PRESENTING ILLNESS:
An 87-year-old female with history of polymyalgia rheumatica (PMR), osteoporosis, mild 
cognitive impairment, insomnia, dyslipidemia, and GERD presented to the hospital in 
June 2018 from her nursing home with complaints of new onset left jaw pain, dysphagia, 
and tongue pain for 1 week.  Two and a half weeks prior to hospitalization, she was 
evaluated by her primary care provider due to symptoms of painful, sore shoulders with 
associated new ambulatory difficulties in the setting of an elevated ESR of 68. She was 
subsequently treated with prednisone 25 mg/d titrated down to 10 mg/d. Her symptoms 
persisted and she presented to the hospital. On admission, labs were unremarkable 
except a WBC of 14.3. CT imaging showed no acute inflammatory process in 
maxillofacial region and CXR was suspicious for left lingular pneumonia which was 
treated with broad spectrum antibiotics. Her tongue lesion was initially evaluated by 
dentistry who felt the etiology was likely due to oral or esophageal candidiasis that 
resulted after prednisone use. She was treated with magic mouthwash and nystatin 
without resolution. She was subsequently seen by Ear, Nose, and Throat and Infectious 
Diseases consultants who felt the tongue ulceration and ecchymosis was due to Herpes 
Simplex I (HSV-1).  She was empirically treated with acyclovir and viscous lidocaine. Her 
hospitalization was complicated by failure of swallow study secondary to tongue pain 
and Dobhoff placement was required. She was discharged on her outpatient prednisone 
dose of 10 mg/d. 
After hospitalization, the patient was referred to Rheumatology and seen on 7/18/18 for 
concern of an atypical presentation of giant cell arteritis. Her tongue pain was improved 
but not resolved and her PMR symptoms were controlled. She denied double vision, 
blurry vision, headache, temporal head tenderness, scalp tenderness and sensitivity.  
Her ESR/CRP were serially monitored to monitor progression of disease (see table 1). 
Due to persistently elevated ESR/CRP in the setting of PMR with unresolved tongue 
lesion, the patient was referred to Vascular Surgery for temporal artery biopsy. She 
underwent bilateral temporal artery biopsy on 9/4/18 with results consistent with 
temporal arteritis. The patient’s dose of prednisone was increased to 40 mg/d and later 
to 50 mg/d with methotrexate for steroid sparing due to persistently elevated CRP. After 
treatment with adequate medication doses, the patient’s tongue lesion improved and 
inflammatory markers decreased. 
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DISCUSSION:
In this case, we describe a patient with polymyalgia rheumatica (PMR) who presented 
with a necrotic tongue ulcer as her main manifestation of giant cell temporal arteritis 
(GCA). Demographics from a systemic review of twenty-five patients with GCA and 
tongue necrosis suggests average age at diagnosis of 77 and 23 of 25 were female.1  
In a British cohort of patients with GCA the presence of tongue and scalp necrosis were 
manifestations of more severe GCA and had higher incidence of visual loss.2 Other 
atypical features have been reported including cough, trismus, hearing loss, and facial 
swelling.3,4,5,6,7 
Patients with GCA present frequently with headaches (90%), polymyalgia rheumatica 
(34%), jaw claudication (50%), and blurred vision (40%).8 Other findings include fever, 
elevated sedimentation rate, and leukocytosis. Ocular symptoms are notably the most 
devastating and treatment should be prompted immediately if suspicion for disease is 
high. Bilateral temporal artery biopsy has been associated with a >90% negative 
predictive value from retrospective data at Mayo Clinic9 though this degree of diagnostic 
accuracy is suspected to be much lower10. GCA can have devastating consequences 
including stroke and irreversible blindness if not treated early. The use of corticosteroids 
continues to be the standard of care. The duration of treatment depends upon tolerability 
of steroid taper. Adjunctive therapies such as methotrexate, azathioprine, dapsone, and 
anti-TNF-alpha agents have been of limited proven benefit.11 The use of tocilizumab, an 
anti-IL-6 agent, along with steroid taper has shown early promising outcomes.12 
CONCLUSION:
Tongue necrosis is not part of the criteria cited by the American College of 
Rheumatology for GCA. 13 However, its presence in a patient with elevated ESR >50mm/
hr with age >50 warrants referral to vascular surgery for temporal artery biopsy. Early 
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Table 1. Trend of CRP and ESR
5/25/18  7/13/18  8/22/18  9/17/18  10/8/18  12/14/18   1/14/19
ESR (mm/hr) 68    71    72
CRP (mg/L)      44.8   35.9   4.8   45.7    12.9     <3.0
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